• There are no suggestions because the search field is empty.

Supporting Market Access to Essential Medicines in Europe

circles-1
BioTech-icon
Pharmaceutical Manufacturer
Tag_icon
Regulatory Affairs
Pharma (2)
Pharma & Biotech

Our client is a leading pharmaceutical manufacturer in Asia, specializing in anesthetics, analgesics, and narcotics. With a strong presence in global markets, the company aimed to introduce a key product to Europe where access to similar treatments remains limited. However, entering the European market required navigating complex regulatory requirements, including obtaining an EU GMP license to ensure compliance with stringent quality and safety standards.

1
Challenge
Challenge
2
Approach
Approach
3
result_icon
Result
Challenge

Challenge

Regulatory & compliance challenges

 

To bring their product to European patients, the company needed to secure an EU GMP license, conduct audits to demonstrate compliance, and establish a solid regulatory strategy.

In addition, they were responsible for compiling and submitting a complete dossier, managing communication with regulatory authorities, and implementing laboratory method transfer to support retesting and Qualified Person (QP) batch release.

Approach

Approach

Ensuring a smooth regulatory pathway

 

QbD Group provided comprehensive regulatory and quality support to to guide the company toward market entry. Our approach included:

  • Conducting audits at the API and finished product manufacturing sites to support the QP declaration.
  • Developing a robust regulatory strategy, compiling the Common Technical Document (CTD) and eCTD for submission.
  • Managing communication with regulatory authorities and addressing deficiency letters to streamline approval.
  • Facilitating laboratory method transfer to ensure smooth retesting and QP batch release processes.
Results

Result

Progressing toward market authorization

 

While the project is still ongoing, significant milestones have been achieved:

  • Submission of key regulatory documentation to support the EU GMP licensing process.
  • Active engagement with competent authorities to address regulatory feedback and refine submission materials.
  • Future pharmacovigilance support planned to ensure ongoing compliance and patient safety.

The ultimate goal remains securing timely Market Authorization Approval enabling the company to introduce its product in Europe and expand patient access to essential treatments.

contact-mail

Get in touch

Looking for expert regulatory support to enter the European market? 

Contact us today to discuss your project and explore how we can support your success.







Get in touch_QbD group-1